Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy
NCT06903923
Not Yet Recruiting
The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 (GLP-1) Semaglutide as compared to those with similar weight followed by lifestyle management. Participants will: * Take Semaglutide as prescribed or continue to work on lifestyle management for weight loss * Take provided calcium and vitamin D supplements * Attend 6 study visits over 24 months with two at the beginning... Read More
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
03/31/2025
Locations: University of Virginia Medical Center, Charlottesville, Virginia
Conditions: Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification, Bone Density, Obesity
Register for Updates
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
NCT00992901
Recruiting
RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been recognized with life-threatening hyperinsulinemic hypoglycemia several years following their surgery. While the mechanisms by which RYGB improves glucose metabolism or alters islet cell function in patients after RYGB are not understood, recent studies suggest that increased secretion of GI hormones,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/12/2025
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Post Bariatricsurgery, Hypoglycemia
Register for Updates
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
NCT04779697
Completed
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/10/2025
Locations: The Yale Stress Center: Yale University, New Haven, Connecticut
Conditions: Obesity
Register for Updates
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
NCT01851694
Recruiting
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has man... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Register for Updates
Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring
NCT06668935
Recruiting
This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: East Coast Institute for Research, LLC, Jacksonville, Florida +1 locations
Conditions: Diabetes Mellitus
Register for Updates
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
NCT06333496
Completed
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight. PURPOSE The purpose of this study is to assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula. SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/03/2024
Locations: Alpine Bio, Salt Lake City, Utah
Conditions: Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity, Heart Health Markers
Register for Updates
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
NCT06682351
Not Yet Recruiting
The study team will invite participants with prediabetes or mild diabetes (HbA1c 5.7-7.0) to join a 5-year research study that will define subphenotypes of type 2 diabetes based on underlying physiology (eg insulin resistance, beta-cell dysfunction, incretin defect, liver insulin resistance) and then test the hypothesis that response to three first-line treatments will vary according to metabolic subphenotype. Variables of interest include glucose, cardiovascular risk markers, and weight. Treatm... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/07/2024
Locations: Stanford University, Stanford, California
Conditions: Prediabetes / Type 2 Diabetes
Register for Updates
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
NCT05073692
Recruiting
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/22/2024
Locations: Romain S. Neugebauer, Oakland, California +5 locations
Conditions: Type 2 Diabetes Mellitus, Cardiovascular Diseases
Register for Updates
Diabetes Remote Intervention to improVe Use of Evidence-based Medications
NCT06046560
Completed
A randomized remote, implementation trial in the Mass General Brigham network was performed on 200 patients with T2D at high CV or kidney risk. The study's primary objective was to create a remote diabetes management platform that improved the initiation and adherence to glucose-lowering medications with CV and kidney benefit and was evaluated by the primary outcome: increasing the proportion of patients with prescriptions for GDMT therapy by 6 months.
Gender:
ALL
Ages:
Between 27 years and 79 years
Trial Updated:
10/21/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Cardiovascular Diseases, Diabetes
Register for Updates
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
NCT05577728
Completed
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates
GLP-1 and Hypoglycemia
NCT01858896
Active Not Recruiting
Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low blood sugar levels have on blood vessels.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
09/04/2024
Locations: University of Maryland, Baltimore, Baltimore, Maryland
Conditions: Type 2 Diabetes Mellitus
Register for Updates
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland +7 locations
Conditions: Type2Diabetes, ASCVD
Register for Updates